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Abstract
Nontuberculous mycobacteria are increasingly recognized as causes of chronic pulmonary disease.
Treatment decisions are guided by the clinical presentation, microbial isolate, and condition of the
patient. Management may include antibiotic therapy, surgical resection, or observation. Definitive
trials are lacking, and optimum management remains uncertain.
Introduction and context
Nontuberculous mycobacteria (NTM) encompass more
than 120 species that are widely distributed in the
environment [1]. The isolation of NTM from respiratory
samples and the prevalence of NTM pulmonary disease
have increased over the past 20 years [1,2]. NTM are
opportunistic pathogens, preying upon individuals with
underlying structural lung disease such as bronchiectasis,
emphysema, and pre-existing cavities from prior infec-
tion or pneumoconiosis; persons with chest wall
abnormalities such as scoliosis and pectus excavatum;
and those with deficiencies of cellular immunity, such as
HIV infection and genetic disorders affecting the inter-
feron-gamma pathway [1,3,4].
There are three general patterns of NTM pulmonary
disease [1]. The fibrocavitary form involves mainly the
upper lobes and commonly occurs in middle-aged male
smokers with underlying chronic obstructive pulmonary
disease, pneumoconiosis, or healed tuberculosis. The
nodular bronchiectatic pattern typically presents in
slender, elderly, non-smoking females and is often
associated with chest wall deformities such as pectus
excavatum. The third form of NTM pulmonary disease is
hypersensitivity pneumonitis, which can result from
exposure to contaminated hot tubs or industrial cool-
ants. In this report, we will focus on the management
of the fibrocavitary and nodular bronchiectatic forms of
NTM pulmonary disease as the management of
hypersensitivity pneumonitis is centered on the avoid-
ance of aerosolized NTM exposure.
The diagnosis of NTM pulmonary disease is challenging
because of the diverse and nonspecific clinical presenta-
tion of these infections and the difficulty in separating
environmental contamination and transient coloniza-
tion from active infection. The natural history of NTM
disease is also highly variable and is influenced by host-
and pathogen-related factors [1,5-7]. Treatment deci-
sions must be tailored to individual patients and focus
on three considerations: antibiotic therapy, surgery, and
the management of underlying diseases. Successful
treatment is hampered by the need for prolonged therapy
with poorly tolerated antibiotics. Definitive guidance
from controlled trials is lacking, and long-term outcomes
often are unsatisfactory.
Recent advances
The prevalence of NTM in respiratory tract specimens
and the number of diagnosed cases of NTM lung disease
have steadily increased in recent decades [2,8,9].
A population screening study in the US demonstrated
that the prevalence of skin test reactivity to Mycobacterium
intracellulare antigen increased from 11.2% in 1971-
1972 to 16.6% in 1999-2000 [10]. These trends likely
result from a combination of factors: increased
awareness among clinicians, widespread use of computed
tomography, advances in detection of mycobacteria,
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the at-risk population. In industrialized nations, the
burden of NTM disease may soon exceed that of
tuberculosis [2,11].
Host factors that predispose individuals to NTM lung
disease remain incompletely understood [12]. Damaged
airway mucosa and impaired mechanical clearance
facilitate NTM infection, which is strongly linked with
bronchiectasis and cystic fibrosis [1,12]. Genetic defi-
ciencies in the interleukin-12/interferon-gamma axis
predispose patients to severe NTM infection [12], and
case reports continue to highlight the risk of NTM disease
associated with tumor necrosis factor blockade [13,14].
In most cases, the origin of NTM disease remains
enigmatic. A careful study of women with NTM
pulmonary disease associatedwith thoracic cageabnorm-
alities and lingular or middle lobe bronchiectasis (Lady
Windermere syndrome) uncovered a high frequency of
CFTR (cystic fibrosis transmembrane conductance reg-
ulator) mutations and mild impairments in interferon-
gamma production, but no specific immunological
defects [5].
In 2007, the American Thoracic Society (ATS) and
Infectious Diseases Society of America (IDSA) published
an updated statement that streamlined the diagnostic
criteria for NTM disease and that provided evidence-
based guidelines for treatment [1]. This very thorough
and well-referenced document should be required
reading for health care providers involved in the
management of patients with NTM infections. The
modified diagnostic criteria include clinical and radio-
graphic features that are compatible with NTM disease,
convincing microbiological evidence (isolation of
NTM from ≥2 sputum samples or from lung washings
or tissue biopsies), and the exclusion of other diagnoses.
Most patients from whom NTM is isolated from
respiratory tract samples will not meet these criteria for
NTM disease [8,9,15].
The optimum antimicrobial treatment for NTM pul-
monary disease has not been determined. The antibiotic
regimens recommended in the ATS/IDSA statement
based on the available evidence are pathogen- and
syndrome-specific and guided by targeted antimicrobial
sensitivity testing. Pulmonary infection with Mycobacter-
ium avium complex (MAC) is the most common cause of
NTM lung disease and serves as a paradigm for the
management of other NTM infections. For initial therapy
for MAC pulmonary disease, susceptibility testing for
clarithromycin is recommended as resistance to this
agent predicts treatment failure and relapse, whereas
susceptibility testing to rifamycins, ethambutol, and
streptomycin does not predict clinical efficacy [1,16-18].
Patients with the nodular bronchiectatic form of MAC
pulmonary disease of mild-to-moderate severity can be
treated with an intermittent regimen of thrice-weekly
macrolide (clarithromycin or azithromycin), ethambu-
tol, and rifampicin [1,19,20]. Daily treatment is recom-
mended for the fibrocavitary form and for severe/
progressive cases of nodular bronchiectatic disease. The
addition of an injectable antimicrobial such as strepto-
mycin should be considered for advanced disease.
Treatment for NTM pulmonary disease should be
continued for 12 months following sputum conversion
to culture negative.
Recent gains in the management of pulmonary MAC
infections have been modest. A randomized controlled
trial of thrice-weekly streptomycin added to thrice-
weekly clarithromycin, rifamycin, and ethambutol
showed improved microbiological efficacy in sputum
conversion (71% versus 50%), but no difference in
symptoms or time to relapse [21]. Inhaled aminoglyco-
sides are a promising alternative to intravenous therapy
in some cases, but experience is limited [22]. Immuno-
therapy with Mycobacterium vaccae was tested in an open-
label trial but did not improve outcome over antibiotic
therapy alone [23]. Drug intolerances that lead to
interruptions in treatment and antibiotic substitutions
remain common in the management of NTM pulmonary
disease, at considerable economic cost [1,23-25].
Surgery can play an important role in the management of
localized NTM pulmonary disease in patients with
adequate cardiopulmonary reserve. Resection should be
considered in cases of treatment failure and in patients
at high risk of treatment failure, such as infection
with macrolide-resistant MAC or Mycobacterium abscessus
[1,3]. Surgical case series have reported sputum clearance
rates of 88-100% and relapse rates of 0-9.5% [26-30].
However, surgical management of NTM lung disease
is associated with substantial risks. In the largest
reported case series (in which 236 patients were treated
from 1983 to 2006), operative mortality was 2.6%
and morbidity was 18.5%, and bronchopleural
fistulae complicated one-third of right pneumo-
nectomies [31].
Implications for clinical practice
NTM pulmonary disease is increasingly common. The
recently published ATS/IDSA statement provides useful
criteria for the diagnosis of NTM disease and rational
guidelines for treatment. However, these recommenda-
tions are based largely on observational studies and
expert opinion, rather than controlled trials. Current
antibiotic regimens often are poorly tolerated, and
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commonly encountered species of NTM. Surgery has a
role in some patients with predominantly focal disease
but should be limited to centers with expertise in both
medical and surgical management of NTM disease. There
is an urgent need for further investigation to better define
optimal antimicrobial regimens and identify new and
more effective treatments.
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